Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN. Reyes-Soffer G, et al. Circulation. 2017 Jan 24;135(4):352-362. doi: 10.1161/CIRCULATIONAHA.116.025253. Epub 2016 Dec 16. Circulation. 2017. PMID: 27986651 Free PMC article. Clinical Trial.
Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human studies characterizing the effects of PCSK9 inhibitors on lipoprotein metabolism
Although studies in mice and cells have identified increased hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, …
Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
Wang M, Zhao D, Xu L, Guo W, Nie L, Lei Y, Long Y, Liu M, Wang Y, Zhang X, Zhang L, Li H, Zhang J, Yuan D, Yue L. Wang M, et al. Metabolism. 2019 May;94:47-58. doi: 10.1016/j.metabol.2019.02.002. Epub 2019 Feb 12. Metabolism. 2019. PMID: 30768966
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in the cholesterol metabolism by negatively regulating the low-density lipoprotein receptor (LDLR). ...Furthermore, alirocumab inhibiting PCSK9 partly …
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in the cholesterol metabolism by negat …
New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects.
Ying Q, Chan DC, Watts GF. Ying Q, et al. Front Physiol. 2021 Feb 10;12:603910. doi: 10.3389/fphys.2021.603910. eCollection 2021. Front Physiol. 2021. PMID: 33643062 Free PMC article. Review.
PCSK9 also regulates the metabolism of lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins (TRLs). ...The effect of PCSK9 inhibition on TRL metabolism has been studied in healthy individuals and in patients with
PCSK9 also regulates the metabolism of lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins (TRLs). ...The
Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
Djebli N, Martinez JM, Lohan L, Khier S, Brunet A, Hurbin F, Fabre D. Djebli N, et al. Clin Pharmacokinet. 2017 Oct;56(10):1155-1171. doi: 10.1007/s40262-016-0505-1. Clin Pharmacokinet. 2017. PMID: 28063030 Free PMC article.
BACKGROUND AND OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 inhibition with monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-cholesterol levels other lipid-lowering therapies. ...CONCLUSIONS: This mechanistic …
BACKGROUND AND OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 inhibition with monoclonal antibodies such as alirocumab